TransCode Therapeutics Appoints Dr. Anna Moore, Inks Research Deal

TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company pioneering immuno-oncology and RNA-based therapies, has announced the appointment of Dr. Anna Moore as Chair of its Scientific Advisory Board and a sponsored research agreement with Michigan State University. These strategic moves aim to advance the company's RNA therapeutic pipeline, particularly its lead candidate, TTX-MC138, which targets metastatic tumors overexpressing microRNA-10b—a well-documented biomarker of metastasis. The agreement with Michigan State University is expected to support the development of TTX-MC138, including evaluation in combination with other therapies, while Dr. Moore will provide strategic guidance on research and development efforts focused on treating advanced cancers.

TransCode Therapeutics is dedicated to developing first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The company's lead candidate, TTX-MC138, is a key focus of the new research agreement, which will explore its potential in combination therapies. Dr. Moore, a renowned expert in molecular imaging and nanomedicine, brings extensive experience to the Scientific Advisory Board, where she will help steer the company's R&D strategy. This appointment and the research collaboration underscore TransCode's commitment to advancing innovative treatments for high-risk and advanced cancers.

The news was disseminated via InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN. InvestorWire offers advanced wire-grade press release syndication and a full array of tailored corporate communications solutions, ensuring maximum reach and impact for companies like TransCode. For investors and followers of TransCode Therapeutics, the latest updates are available in the company's newsroom at https://ibn.fm/RNAZ, while the full press release can be accessed at https://ibn.fm/NA2NH.